$GBT News
Last published 1y ago
- 1y agoDVAXMRNASNYTARS+4Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow ShareholdersBusiness WireBelieves Company's Misguided Acquisition Strategy is Destroying Value and Preventing Dynavax from Maximizing the Opportunities of Heplisav for Shareholders and Patients In Deep Track's View, Properly Focusing on
- 1y agoAVTEDVAXHZNPMRNA+7Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual MeetingBusiness WireIssues Letter to Fellow Shareholders Detailing Why Truly Independent Voices – Including a Shareholder Representative – Are Needed in the Dynavax Boardroom
- 4y agoGBTGBT Supports the Sickle Cell Disease Treatment Centers Act of 2022GlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) announced its support for the Sickle Cell Disease Treatment Centers Act of 2022, which was introduced today and, if passed in its curre
- 4y agoGBTGBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 11th Annual Sickle Cell Disease (SCD) T
- 4y agoPLTRSGFYCVSGBT+8Stocks making the biggest moves in the premarket: Palantir, Signify Health, Global Blood Therapeutics and moreCNBCThe stocks making the biggest moves in premarket trading include Palantir, Signify Health, Global Blood Therapeutics, and more.
- 4y agoGBTPFEPfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare HematologyBusiness WireProposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion Potential to address the full spectrum of critical needs in t
- 4y agoGBTPFEPfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare HematologyGlobeNewswireProposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion Potential to address the full spectrum of critical needs in th
- 4y agoGBTGBT Announces New Employment Inducement GrantsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on August 1, 2022, the compensation committee of GBT's board of directors granted 10 new employees restricted sto
- 4y agoGBTGBT Announces Participation at the Wedbush PacGrow Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will participate in a virtual fireside chat at the Wedbush PacGrow Healthcare Conference on Wednesday, August 10,
- 4y agoGBTGBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022GlobeNewswireSOUTH SAN FRANCISCO, Calif., July 29, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after U.S. financial markets close
- 4y agoGBTMHRA Grants Marketing Authorization for GBT's Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and OlderGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Great Britain marketing authorization for
- 4y agoGBTGBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in BrazilGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the initiation of an expanded access program (EAP) for voxelotor in Brazil for the treatment of sickle cell disease (SCD)
- 4y agoGBTThe GBT Foundation Awards $250,000 in ACE Grants to Support Sickle Cell Disease Community-Based OrganizationsGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood Therapeutics, Inc. (GBT), has awarded grants of approximately $50,000 each to five community-based organizati
- 4y agoGBTGBT Announces New Employment Inducement GrantsGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 07, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on July 1, 2022, the compensation committee of GBT's board of directors granted 22 new employees options to purch
- 4y agoGBTGBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell DiseaseGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it initiated the Phase 2 portion of a planned Phase 2/3 trial of GBT021601 (GBT601), the company's investigational n
- 4y agoGBTNFL Running Back Tevin Coleman and Family Team Up with GBT to Share Playbook for Families Affected by Sickle Cell DiseaseGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced a new partnership with New York Jets running back Tevin Coleman and his wife, Akilah, whose 4-year-old daughter lives wit
- 4y agoGBTNew GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell DiseaseGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced results from the Sickle Cell Health Awareness, Perspectives and Experiences (SHAPE) survey, a multinational survey on the
- 4y agoGBTGBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell DiseaseGlobeNewswirePositive results from Phase 1 study of GBT601, including incremental new data, support advancing into planned Phase 2/3 trial by mid-year GBT to hold investor conference call and webcast today at 3:00 p.m. CEST (9:00 a.m. EDT) to highlight EHA data an
- 4y agoGBTThe GBT Foundation Opens 2022 ACCEL Grant Program to Provide Up to $500,000 in Support to Sickle Cell Disease Nonprofit Healthcare Organizations and InstitutionsGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood Therapeutics, Inc. (GBT), today announced that it is accepting proposals for the fourth annual Access to Excell
- 4y agoGBTGBT's Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell DiseaseGlobeNewswireInclacumab is a novel P-selectin inhibitor currently in Phase 3 clinical trials to reduce vaso-occlusive crises (VOCs) and readmissions due to VOCs in patients with sickle cell disease GBT601 is a next generation sickle hemoglobin (HbS) polymerization
- 4y agoGBTGBT Announces New Employment Inducement GrantsGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on June 1, 2022, the compensation committee of GBT's board of directors granted 10 new employees restricted stock
- 4y agoGBTGBT to Host Investor Conference Call on Friday, June 10 and Participate in Upcoming Investor ConferencesGlobeNewswireConference call and webcast will include data presented at EHA 2022 and business and R&D updates Company to also participate in the William Blair and Goldman Sachs investor conferences SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -
- 4y agoGBTGBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 CongressGlobeNewswireNew real-world evidence data on Oxbryta® (voxelotor) from multicenter RETRO Study and new Phase 1 data on GBT601 to be highlighted SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) to
- 4y agoGBTGBT Announces Participation in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will participate in fireside chats at the following investor conferences: Bank of America Securities 2022 Heal
- 4y agoGBTGBT Announces New Employment Inducement GrantsGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on May 1, 2022, the compensation committee of GBT's board of directors granted 14 new employees restricted stock u
- 4y agoGBTGBT Reports First Quarter 2022 Financial ResultsGlobeNewswireAchieved Oxbryta® (voxelotor) net revenues of $55.2 million in the first quarter 2022, a 41% increase year over year Strong new prescription growth driven by the recent launch for children ages 4 to less than 12 years and improving trends for patie
- 4y agoGBTGlobal Blood Therapeutics (GBT) Q1 2022 Earnings Call TranscriptEarnings Call TranscriptsGBT earnings call for the period ending March 31, 2022.
- 4y agoGBTGBT Launches Inaugural Environmental, Social and Governance (ESG) ReportGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company dedicated to meeting the needs of underserved patient communities starting with sickle cell disease (SCD), t
- 4y agoGBTGBT to Announce First Quarter 2022 Financial Results on Wednesday, May 4, 2022GlobeNewswireSOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022, after U.S. financial markets close.
- 4y agoGBTGBT Announces New Employment Inducement GrantsGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on April 1, 2022, the compensation committee of GBT's board of directors granted 21 new employees restricted s
- 4y agoGBTGBT Announces Participation at the Guggenheim Genomic Medicines & Rare Disease DayGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will participate in a virtual fireside chat at the Guggenheim Genomic Medicines & Rare Disease Day on Friday, Ap
- 4y agoGBTGBT Announces New Employment Inducement GrantsGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on March 1, 2022, the compensation committee of GBT's board of directors granted 19 new employees restricted s
- 4y agoGBTThe GBT Foundation Opens 2022 ACE Grant Program, Providing up to $250,000 in Support to Sickle Cell Disease Community-Based OrganizationsGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood Therapeutics, Inc. (GBT), today announced it is accepting proposals for the Access to Care Empowerment for Sic
- 4y agoGBTGBT Announces Participation in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will participate in virtual fireside chats at the following investor conferences: Cowen 42nd Annual Health Ca
- 4y agoGBTGBT Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewswireAchieved Oxbryta® (voxelotor) net revenues of $56.1 million in the fourth quarter and $194.7 million for full year 2021, a 57% increase year over year Executed on key growth opportunities highlighted by pediatric label expansion in the U.S., marketin
- 4y agoGBTGlobal Blood Therapeutics (GBT) Q4 2021 Earnings Call TranscriptEarnings Call TranscriptsGBT earnings call for the period ending December 31, 2021.
- 4y agoGBTGBT to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 23, 2022GlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will report fourth quarter and full year 2021 financial results on Wednesday, February 23, 2022, after U.S. finan
- 4y agoGBTEuropean Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and OlderGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the European Commission (EC) has granted Marketing Authorization for Oxbryta® (voxelotor) for the treatment of hemolytic
- 4y agoGBTGBT Announces New Employment Inducement GrantsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on February 1, 2022, the compensation committee of GBT's board of directors granted 21 new employees options to pur
- 4y agoGBTOxbryta® (voxelotor) Tablets for Oral Suspension, A New Dispersible Tablet Dosage Form, Now Available for Patients with Sickle Cell Disease in the United StatesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced Oxbryta® (voxelotor) tablets for oral suspension, a new dispersible, once-daily tablet dosage form recently approved by
- 4y agoGBTGBT Announces New Employment Inducement GrantsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on January 1, 2022, the compensation committee of GBT's board of directors granted 10 new employees options to purc
- 4y agoGBTGBT to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 11:15 a.m. E.T.
- 4y agoGBTU.S. FDA Approves Supplemental New Drug Application for Expanded Indication of Oxbryta® (voxelotor) for Children as Young as 4 Years of Age with Sickle Cell DiseaseGlobeNewswireNew dispersible tablet dosage form also approved Oxbryta is the first medicine that addresses the root cause of red blood cell sickling SOUTH SAN FRANCISCO, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ
- 4y agoGBTGBT's Oxbryta® (voxelotor) Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and OlderGlobeNewswireEuropean Commission decision on marketing authorization anticipated first quarter of 2022 Oxbryta would be the first oral treatment available in Europe to directly inhibit sickle hemoglobin (HbS) polymerization, the underlying molecular cause of sickl
- 4y agoGBTGBT Announces Pricing of Upsized Offering of $300.0 Million of Convertible Senior NotesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the pricing of $300.0 million aggregate principal amount of its Convertible Senior Notes due 2028 (the "notes") in a priva
- 4y agoGBTGBT Announces Proposed Offering of $250.0 Million of Convertible Senior NotesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it intends to offer $250.0 million aggregate principal amount of its Convertible Senior Notes due 2028 (the "notes")
- 4y agoGBTGBT Presents Positive Results from Phase 1 Study of GBT021601 in Patients with Sickle Cell Disease and Healthy Volunteers at ASH Annual Meeting and ExpositionGlobeNewswireGBT601 demonstrated average hemoglobin occupancy of greater than 30% with 100 mg daily doses in a multiple ascending dose study of six adult SCD patients GBT601 tolerability was favorable in studies of SCD patients and healthy volunteers Study
- 4y agoGBTGBT Presents Positive New Data on Oxbryta® (voxelotor) in Patients with Sickle Cell Disease at ASH Annual Meeting and ExpositionGlobeNewswireReal-world experience study of more than 3,100 patients demonstrates statistically significant reductions in transfusions, vaso-occlusive crises and hospitalizations in patients treated with Oxbryta Phase 1 study of inclacumab also presented at ASH su
- 4y agoGBTGBT Announces New Employment Inducement GrantsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on December 1, 2021, the compensation committee of GBT's board of directors granted 24 new employees restricted s
- 4y agoGBTGBT Supports the ASH Research Collaborative's Data Hub Sickle Cell Disease ProgramGlobeNewswireWASHINGTON and SOUTH SAN FRANCISCO, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- The ASH Research Collaborative (ASH RC), a non-profit organization established in 2018 by the American Society of Hematology (ASH), and Global Blood Therapeutics, Inc. (GBT)